Dylan Trundell
Welwyn Garden City, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Journal: Lancet (London, England)
Published: February 02, 2026
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Journal: NPJ Parkinson's disease
Published: August 13, 2025
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.
Journal: Journal of Parkinson's disease
Published: February 20, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Journal: Parkinsonism & related disorders
Published: November 02, 2024
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Journal: NPJ Parkinson's disease
Published: September 13, 2024
Tominersen in Adults with Manifest Huntington's Disease.
Journal: The New England journal of medicine
Published: December 06, 2023
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Journal: Nature medicine
Published: June 30, 2023
Development of the SMA independence scale-upper limb module (SMAIS-ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA.
Journal: Journal of the neurological sciences
Published: November 16, 2021
Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts: Potential Applications in Rare Disease.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: October 12, 2021
Self-Report versus Clinician Examination in Early Parkinson's Disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: August 17, 2021
Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy.
Journal: Neurology and therapy
Published: May 30, 2020
Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy.
Journal: PloS one
Published: January 21, 2020
Last Updated: 09/26/2026